Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. It is researched most often for Weight management, Blood sugar regulation and Metabolic health. Phase III clinical trials — investigational, not yet approved. This guide walks through what Retatrutide is, how it's studied, what it's commonly combined with, and — just as important — where the science stops. It's educational information only, not medical advice.
What is Retatrutide?
Retatrutide is an investigational "triple agonist" that activates the GIP, GLP-1 and glucagon receptors simultaneously. It has drawn attention for producing substantial weight reduction in clinical trials and is being studied for obesity and metabolic disease.
Also known as: Reta, LY3437943.
How does Retatrutide work?
Retatrutide is an investigational "triple agonist" that simultaneously activates the GIP, GLP-1, and glucagon receptors. Adding glucagon-receptor activity is thought to increase energy expenditure on top of the appetite and glycemic effects of GIP/GLP-1, and early trials have shown substantial weight reduction.
What is Retatrutide researched for?
In the research and community discussion, Retatrutide comes up most often in connection with Weight management, Blood sugar regulation and Metabolic health. Remember that "researched for" is not the same as "proven to treat" — these are the directions the science has explored, not established outcomes.
- Weight management
- Blood sugar regulation
- Metabolic health
What does the research actually show?
Phase III clinical trials — investigational, not yet approved. The honest framing matters here: promising mechanisms and early results are genuinely interesting, but they are not the same as proven, approved therapy. Anyone presenting Retatrutide as a guaranteed treatment is getting ahead of the evidence.
Safety and considerations
Not FDA-approved. Prescription-grade investigational compound; use only under medical supervision. Because the responsible framing is educational rather than prescriptive, Selpho provides no dosing, protocols, or purchase links, and always points back to a licensed professional for any decision. If you are dealing with a real health concern, that professional — not a peptide — is where planning should start.
Where to learn more about Retatrutide
To go deeper, see the Retatrutide library page for a quick reference; published research on PubMed; Selpho's free AI Peptide Advisor to see where Retatrutide might fit your goals.
Frequently asked questions
An investigational triple GIP/GLP-1/glucagon receptor agonist studied for obesity and metabolic disease. It has drawn attention for strong weight-loss results in trials.
No. It is investigational and in clinical trials — not FDA-approved and not commercially available as a medicine.
It adds glucagon-receptor activity to the incretin mechanisms, targeting three receptors instead of one or two. It remains under study.
Not sure if Retatrutide fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis guide is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.